In our study, although the use of GLP-1 RAs was associated with a modest increase in the rate of incident DR (0.2% increase) over 2 years, the absolute number of new DR diagnoses was low at 2.7%, likely below the expected annual incidence in US patients with T2D.28 Furthermore, GLP-1 RA use was associated with a 24.2% reduction in the risk of vision loss progressing to blindness, with 30.2% reduction in patients with preexisting DR. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.